In clinical trials, glioblastoma patients with IDH1 R132H treated with vandetanib or ivosidenib in combination with temozolomide showed a significant increase in overall survival (OS) compared to glioblastoma patients without IDH1 R132H [48,49,50]. Here, IDH1 is linked to glioblastoma.